1. Ma SY, Röyttä M, Rinne JO, Collan Y, Rinne UK. Correlation
between neuromorphometry in the substantia nigra and clinical
features in Parkinson’s disease using disector counts. J Neurol Sci.
1997;151:83–7.
2. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler
CH, et al. Disease duration and the integrity of the nigrostriatal
system in Parkinson’s disease. Brain. 2013;136:2419–31.
3. Zucca FA, Bellei C, Giannelli S, Terreni MR, Gallorini M, Rizzio
E, et al. Neuromelanin and iron in human locus coeruleus and
substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm (Vienna). 2006;113:757–67.
4. Sulzer D, Cassidy C, Horga G, Kang UJ, Fahn S, Casella L, et al.
Neuromelanin detection by magnetic resonance imaging (MRI)
and its promise as a biomarker for Parkinson’s disease. NPJ Parkinsons Dis. 2018;4:11.
5. de la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J,
Ramachandiran N, Au WL, et al. Age-specific progression of
nigrostriatal dysfunction in Parkinson’s disease. Ann Neurol.
2011;69:803–10.
6. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia
nigra regional selectivity. Brain. 1991;114(Pt 5):2283–301.
7. Matsuura K, Maeda M, Tabei KI, Umino M, Kajikawa H, Satoh
M, et al. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci Lett.
2016;633:112–7.
8. Reimão S, Pita Lobo P, Neutel D, Correia Guedes L, Coelho M,
Rosa MM, et al. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson’s disease patients. Eur J Neurol. 2015;22:540–6.
9. Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP. In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology.
2017;283:789–98.
10. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K,
Tsuchiya K, et al. Neuromelanin magnetic resonance imaging of
locus ceruleus and substantia nigra in Parkinson’s disease. NeuroReport. 2006;17:1215–8.
11. Trujillo P, Summers PE, Ferrari E, Zucca FA, Sturini M, Mainardi
LT, et al. Contrast mechanisms associated with neuromelaninMRI. Magn Reson Med. 2017;78:1790–800.
Japanese Journal of Radiology (2023) 41:1216–1225 12. Nakane T, Nihashi T, Kawai H, Naganawa S. Visualization of
neuromelanin in the Substantia nigra and locus ceruleus at 1.5T
using a 3D-gradient echo sequence with magnetization transfer
contrast. Magn Reson Med Sci. 2008;7:205–10.
13. Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp
ME, et al. Neuromelanin-sensitive MRI as a noninvasive proxy
measure of dopamine function in the human brain. Proc Natl Acad
Sci U S A. 2019;116:5108–17.
14. Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero
J, Callaghan MF, et al. Locus coeruleus imaging as a biomarker
for noradrenergic dysfunction in neurodegenerative diseases.
Brain. 2019;142:2558–71.
15. Chen X, Huddleston DE, Langley J, Ahn S, Barnum CJ, Factor
SA, et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn
Reson Imaging. 2014;32:1301–6.
16. Martín-Bastida A, Lao-Kaim NP, Roussakis AA, Searle GE, Xing
Y, Gunn RN, et al. Relationship between neuromelanin and dopamine terminals within the Parkinson’s nigrostriatal system. Brain.
2019;142:2023–36.
17. Langley J, Huddleston DE, Chen X, Sedlacik J, Zachariah N, Hu
X. A multicontrast approach for comprehensive imaging of substantia nigra. Neuroimage. 2015;112:7–13.
18. Isaias IU, Trujillo P, Summers P, Marotta G, Mainardi L, Pezzoli G, et al. Neuromelanin Imaging and Dopaminergic Loss in
Parkinson’s Disease. Front Aging Neurosci. 2016;8:196.
19. Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H,
et al. 3D neuromelanin-sensitive magnetic resonance imaging
with semi-automated volume measurement of the substantia nigra
pars compacta for diagnosis of Parkinson’s disease. Neuroradiology. 2013;55:719–24.
20. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC)
and tissue water proton relaxation in vivo. Magn Reson Med.
1989;10:135–44.
21. Kusama M, Sato N, Kimura Y, Miyagi K. Quick MR neuromelanin imaging using a chemical shift selective pulse. Magn Reson
Med Sci. 2021;20:106–11.
22. Oshima S, Fushimi Y, Okada T, Nakajima S, Yokota Y, Shima A,
et al. Neuromelanin-sensitive magnetic resonance imaging using
DANTE pulse. Mov Disord. 2021;36:874–82.
23. Wengler K, He X, Abi-Dargham A, Horga G. Reproducibility
assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. Neuroimage. 2020;208: 116457.
24. Kidoh M, Shinoda K, Kitajima M, Isogawa K, Nambu M, Uetani
H, et al. Deep learning based noise reduction for brain MR imaging: tests on phantoms and healthy volunteers. Magn Reson Med
Sci. 2020;19:195–206.
25. Ueda T, Ohno Y, Yamamoto K, Iwase A, Fukuba T, Hanamatsu
S, et al. Compressed sensing and deep learning reconstruction
for women’s pelvic MRI denoising: Utility for improving image
quality and examination time in routine clinical practice. Eur J
Radiol. 2021;134: 109430.
26. Kim M, Kim HS, Kim HJ, Park JE, Park SY, Kim YH, et al.
Thin-slice pituitary MRI with deep learning-based reconstruction: diagnostic performance in a postoperative setting. Radiology.
2021;298:114–22.
1225
27. Wataya T, Nakanishi K, Suzuki Y, Kido S, Tomiyama N. Introduction to deep learning: minimum essence required to launch a
research. Jpn J Radiol. 2020;38:907–21.
28. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel
W, et al. MDS clinical diagnostic criteria for Parkinson’s disease.
Mov Disord. 2015;30:1591–601.
29. Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru
K, et al. Neuromelanin magnetic resonance imaging in Parkinson’s
disease and multiple system atrophy. Eur Neurol. 2013;70:70–7.
30. Uetani H, Nakaura T, Kitajima M, Yamashita Y, Hamasaki T,
Tateishi M, et al. A preliminary study of deep learning-based
reconstruction specialized for denoising in high-frequency
domain: usefulness in high-resolution three-dimensional magnetic
resonance cisternography of the cerebellopontine angle. Neuroradiology. 2021;63:63–71.
31. Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O,
Ortega-Cubero S, Puigvert M, Uranga J, et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson’s disease. Mov Disord. 2015;30:945–52.
32. Wang S, Wu T, Cai Y, Yu Y, Chen X, Wang L. Neuromelanin
magnetic resonance imaging of substantia nigra and locus coeruleus in Parkinson’s disease with freezing of gait. Front Aging
Neurosci. 2023;15:1060935.
33. Liu Y, Li J, He N, Chen Y, Jin Z, Yan F, et al. Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus
using a magnetization transfer contrast prepared 3D gradient
recalled echo sequence. Neuroimage. 2020;218: 116935.
34. Shinde S, Prasad S, Saboo Y, Kaushick R, Saini J, Pal PK, et al.
Predictive markers for Parkinson’s disease using deep neural
nets on neuromelanin sensitive MRI. Neuroimage Clin. 2019;22:
101748.
35. Le Berre A, Kamagata K, Otsuka Y, Andica C, Hatano T, Saccenti L, et al. Convolutional neural network-based segmentation
can help in assessing the substantia nigra in neuromelanin MRI.
Neuroradiology. 2019;61:1387–95.
36. Krupicka R, Marecek S, Mala C, Lang M, Klempir O, Duspivova
T, et al. Automatic substantia nigra segmentation in neuromelanin-sensitive MRI by deep neural network in patients with prodromal and manifest synucleinopathy. Physiol Res. 2019;68:S453–8.
37. Gaurav R, Pyatigorskaya N, Biondetti E, Valabregue R, YahiaCherif L, Mangone G, et al. Deep learning-based neuromelanin
MRI changes of isolated REM sleep behavior disorder. Mov Disord. 2022;37:1064–9.
38. Shin DH, Heo H, Song S, Shin NY, Nam Y, Yoo SW, et al. Automated assessment of the substantia nigra on susceptibility mapweighted imaging using deep convolutional neural networks for
diagnosis of Idiopathic Parkinson’s disease. Parkinsonism Relat
Disord. 2021;85:84–90.
Publisher's Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
13
...
論文の公開元へ
